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Methylmercury is aubiquitous environmental pollutant and a potent neurotoxin. Treatment of
methylmercury poiso relies almost exclusively on the use ofchelating agents to accelerate
excretion ofthe metal. The present studydemonstrates that oral administration ofN-acetylcys-
teine (NAC), awidelyavaiable andlargely nontoxic amino acidderivative, produces aprofound
acceleration ofurinary methylmercuryexcretion in mice. Mice thatreeived NAC in the drink-
ingwater (10mglml) starting at48 hr after methylmercury amiaion excreted from 47 to
54% ofthe 203Hg in urine over the subsequent 48 ir, as compared to 4-10% excretion in con-
trol animals. When NAC-containig water wastgiven fromthe time ofmethylmercury adminis-
tration, itwas evenmoreeffectveatenhancingurinarymethylmercuryexcretonand at lowering
tisue mercurylevels. In contrast, excretion ofinorgnic mercurywas not affeced by oral NAC
administration. The ability ofNAC to enhance methylnercury excretion when given orally, its
relatively low toxicity, and its wide ailability in the clinicalsting indicate that it may be an
ideal therapeutic agent for use in methylmercury poisoning. Key words: antidote, brain, gln-
tathione, inorganic mercury, methylmercury, N-acetylcysteine, poisoning. Environ Health
Prect106:267-271 (1998). [Online 31 March 1998]
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Human exposure to methylmercury occurs
mostly through consumption of fish and
other seafood, although several major inad-
vertent exposures have also occurred,
including epidemics in Japan (Minamata
disease), Iraq, Pakistan, and Guatemala
(1-3). Exposure may also occur in research
laboratories, as evidenced by the recent fatal
poisoning of a chemist at Dartmouth
College (4).
Individuals poisoned with methylmer-
cury exhibit severe neurological distur-
bances, including paresthesia, ataxia, sensory
and speech impairment, and visual field
constriction (1-3). These clinical symptoms
become evident only after a relatively long
latent period of 1-2 months. Because the
damage to the central nervous system
appears to be irreversible, treatment must be
initiated promptly after exposure (3,5). The
only way to prevent or ameliorate toxicity
once methylmercury has been ingested is to
accelerate its elimination from thebody.
Strategies for removing methylmercury
indude hemodialysis, exchange transfusion,
and chelation therapy, with the latter being
the least invasive and most common thera-
peutic intervention (3,5,6). Although many
chelating agents have been tested over the
past four decades, no single best agent has
yet been identified for use in methylmercury
poisoning. Of the agents that have been
examined, meso-2,3-dimercaptosuccinic acid
(DMSA, succimer) and 2,3-dimercapto-1-
propanesulfonic acid (DMPS, Dimaval) are
the most efficient at enhancing methylmer-
cury excretion and in preventing toxicity in
both experimental animals (7-16) and
humans (5,6,17). However, these agents
have limited stability in solution, limited
availability forhuman use, and apropensity
to mobilize other essential and nonessential
metals (18-21).
Surprisingly, the possible use of N-
acetylcysteine (NAC) as a methylmercury
chelating agent has not been previously
evaluated. This omission is probably relat-
ed to three factors. First, NAC was found
to be ineffective at accelerating excretion of
divalent toxic metals, including inorganic
mercury, Hg2+ (22-28), and conflicting
results have been reported regarding the
ability of NAC to protect against
methylmercury-induced embryotoxicity
(29,30). Second, compounds that are
structurally related to NAC, namely, N-
acetyl-penicillamine (N-acetyl-P, P-
dimethylcysteine) and penicillamine itself,
are only minimally effective in accelerating
methylmercury excretion (5,15). Third,
because some NAC is converted to cysteine
(31), an amino acid that increases
methylmercury delivery to its target site,
the brain (32,33), its use would appear to
be contraindicated.
However, in two studies in which NAC
was used in conjunction with hemodialysis
of methylmercury-contaminated human
blood, this chelator was quite effective at
enhancing methylmercury clearance from
blood (17,34). Lund and her collaborators
(17) noted a striking increase in urinary
methylmercury excretion during, as well as
following, hemodialysis in a patient with
acute methylmercury poisoning. These
investigators suggested that NAC should be
examined furtheras apossible methylmercury
antidote. The presentstudysupports this sug-
gestion bydemonstratingthatNACproduces
a dramatic acceleration of methylmercury
excretionwhenadministeredorallyto mice.
Experimental Procedures
Methylmercury chloride was obtained from
ICN (Plainsville, NY), and203HgC12waspur-
chased from Amersham Corporation
(Arlington Heights, IL). CH3203HgCI was
synthesized from 203HgC12 by the method of
Toribara (35). Weconfirmedthepurityofthe
synthesized CH3203HgC1 using cold vapor
atomic absorption (36). The product con-
tained less than 1% inorganic mercury impu-
rity. NAC was purchased from Sigma
Chemical Company (St. Louis, MO). It was
dissolved inwater, thepH adjusted to 6.7-6.8
by adding 5 M NaOH, and diluted to a final
concentration of 10 mg/ml. We prepared
freshNACsolutions every2-3 days.
Female and male C57B1/6 mice (15-26
g, 8 weeks of age) were obtained from
Jackson Laboratory, Bar Harbor, Maine,
and from Baylor College of Medicine,
Houston, Texas. The animals were main-
tained on Purina Mills laboratory chow
with water adlibitum in a temperature-con-
trolled room with a 12-hr alternating light
cycle. Experiments were conducted in
accordance with the guidelines of the
National Institutes of Health for care of
laboratoryanimals.
Micewereplacedindividually instainless-
steel metabolic cages (Lab Products Inc.,
Rochelle Park, NJ) andwere allowed to accli-
mate to the cages for 3-4 days. Urine and
feces were collected onto plastic-lined
absorbent bench paper placed underneath
each cage. Feces was separated from the
urine-stained paper, and each was stored in a
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jli* small plastic bag. Some mice were given
NAG in their drinking water starting 48 hr
before mercury administration. Mice were
injected intraperitoneally with 203Hg-labeled
methylmercury chloride (0.5 or 25 pmol/kg
bodyweight) or 203HgC12 (0.5 pmol/kg, ip).
Injection solutions were prepared in Krebs-
Henseleit buffer and administered in a vol-
ume of 10 ml/kg body weight (20 pCi/kg).
Body burden and urinary and fecal 203Hg
content were measured daily in a Packard
model 3002 gamma counter. We counted
203Hg standards prepared from the dosing
solutions dailyin thesame instrument to cor-
4 -
5 rectfordecayandcounterefficiency.
After 5 days, micewereanesthetizedwith
sodium pentobarbital (55 mg/kg, ip), and
3Hg-labeled selected tissues (liver, kidney, brain, and
Ile (F) C57B1/6 whole blood) were taken for glutathione
h 0.5 pmol/kg (GSH) and 203Hg analysis. The animals
8 hr, some of were killed between 1300 and 1600 hr.
Whole blood was withdrawn from the are means ±+ boia ~~'i
in each group abdomnal vena cava. The median lobe of
rs are smaller the liver, one kidney, the brain, and 0.2-0.3
ml ofwhole blood were each placed in tared
tubes containing 5 ml of2.5% sulfosalicylic
acid/0.25 mM acivicin for subsequent GSH
determination, as described previously (37).
We counted the brain and blood samples
using a Packard model 3002 gamma counter
for 30 sec each and then homogenized the
samples. Liver and kidney samples were
homogenized immediately. The rest of the
liver and the other kidney were removed,
weighed, and used for 203Hg determination.
Urine was withdrawn from the bladders of
some ofthe animals usinga 1-ml syringe and
27-gauge needle for analysis ofNAC con-
tent. Urinesamples were treated with dithio-
threitol to reduce disulfide linkages, deriva-
tized with 1-fluoro-2,4-dinitrobenzene (38),
B thenanalyzed for NAC using an HPLC pro-
tocolpreviouslydescribed (39).
Results
Male and female C57B1/6 mice treated
acutely with CH3203HgCl (0.5 pmol/kg
body weight) excreted 59% and 28% of
the dose in 5 days, respectively (Fig. 1).
This corresponds to a biological half-life of
approximately 4 days in males and 9 days
in females, values comparable to those
reported in previous studies ofmice (9,13).
Urinary excretion of203Hg was approxi-
mately three times higher in male mice
(Fig. 2A), whereas fecal excretion was simi-
lar between males and females (Fig. 2B).
In contrast with this relatively slow rate
of excretion in control animals, mice that
received NAC in their drinking water
beginning 48 hr after methylmercury
administration excreted 91-94% of the
dose during the same time period (Fig. 1).
Most ofthe methylmercury was excreted in
urine (Fig. 2A). NAC had no effect on fecal
203Hgexcretion (Fig. 2B).
NAC efficiently mobilized methylmer-
cury from all tissues examined, induding the
brain (Table 1). The203Hg content ofblood,
kidneys, and liver in mice that received NAC
was approximately 10-20% that ofcontrol
animals, whereas brain levels were decreased
to aboutone-halfthoseofcontrols (Table 1).
Mice that received NAC in their drinking
waterfromthetimeofmethylmercuryadmin-
istration exhibited an even more dramatic
acceleration ofwhole-body203Hg elimination
(Fig. 3) andurinaryexcretion (Fig. 4A). These
animals excreted 87% of the methylmercury
dose inonly2 days (Fig. 3). Conversely, when
NAC was removed from the drinking water,
there was an abrupt decrease in methylmer-
cury excretion (Fig. 3). The biological half-life
for methylmercury after cessation ofNAC
administration, as assessed from the slope of
the line, was similar to that in mice that did
notreceiveNAC(Fig. 3).
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Figure 2. Cumulative (A) urinary and (B) fecal
excretion of203Hg in male (M) and female (F) mice
that received 0.5 pmol/kg body weight of
CH3203HgCU.After48 hr, some ofthe mice received
N-acetylcysteine (NAC) in their drinking water (10
mg/mi). Values are means ± standard errors of
fourto five mice in each group.
Table 1.Tissue 203Hg distribution 5 days afteradministration of0.5 pmol/kg ofeitherCH32°HgCI or203HgCI2to
male and female mice in the presence and absence of 10 mg/mI of N-acetylcysteine (NAC) in the drinking
water(dosing days2-5)
Percentofdose
n Whole blood Kidneys Liver Brain
CH3203HgCI
Males
Control 4 1.14 ± 0.11 5.25 ± 0.28 4.27 ± 0.35 0.54 ± 0.02
NAC 5 0.15 ± 0.07* 0.47 ± 0.03* 1.06 ± 0.12* 0.32 ± 0.02*
Females
Control 4 2.28 ± 0.22 4.28 ± 0.37 10.68 ± 0.72 1.01 ± 0.12
NAC 5 0.21 ± 0.04* 0.64 ± 0.08* 2.33 ± 0.19* 0.42 ± 0.02*
203HgC12
Males
Control 4 0.24 ± 0.03 7.08 ± 0.55 1.94± 0.03 0.09± 0.02
NAC 5 0.18 ± 0.05 3.24 ± 0.37* 2.02 ± 0.13 0.06 ± 0.01
Females
Control 4 0.22 ± 0.05 5.35 ± 0.60 3.29 ± 0.13 0.11 ± 0.01
NAC 5 0.16 ±0.03 3.31 ± 0.41* 4.29± 0.57 0.11 ± 0.01
Values are means± standard errors. Blood 2Hg contentwas calculated assuming a bloodvolume of55mVkg bodyweight
*Significantly differentfrom control (p<0.05) using Student's t-test.
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NAC was also effective in mice given a
50-fold larger dose ofmethylmercury chlo-
ride, 25 jmol/kg bodyweight (Fig. 5). This
dose is at the threshold of toxicity in mice
(16), but no clinical signs of toxicity were
noted in the present study. The results at
this higher dose were similar to those at the
lower dose, except that the biological half-
life was somewhat longer (compare Figs. 3
and 5). Control animals excreted 16% of
the methylmercury dose during the first 2
days (Fig. 5). In contrast, mice that received
NAC in the drinking water excreted 75%
of the dose in the first 2 days (Fig. 5).
When NAC was provided 2 days after
methylmercury administration, there was
an abrupt increase in 203Hg excretion: the
body burden decreased from 84% to 16%
of the original dose in 3 days (Fig. 5).
Withdrawal of NAC once again reverted
the biological half-life ofmethylmercury to
that seen in control animals (Fig. 5).
In contrast to methylmercury, excretion
of inorganic mercury was faster (a t112 of
<2 days) and was not stimulated by NAC
(Fig. 6). However, there was a significant
tissue redistribution of 203Hg in animals
that received NAC (Table 1), which may
contribute to the lack of effect on whole-
body elimination of inorganic mercury.
Kidney levels of203Hg were lower in mice
that received NAC (Table 1). This redistri-
bution away from kidneys (which contain
approximately one-third of the body bur-
den) may limit the amount ofmercury that
can be excreted in urine.
Glutathione levels in liver, kidney,
brain, and whole blood were also measured
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0.5 pmol/kg body weight of CH3203HgCI. One group
of mice received NAC in the drinking water (10
mg/mi) for the first 48 hr after dosing with
methylmercury, whereas the other group received
N-acetylcysteine (NAC) in the drinking water from
days 2 to 5. Values are means ± standard errors of
five mice in each group.
at necropsy; no differences between control
and NAC-treated mice were seen (data not
shown). Thus, although some of the NAC
may be converted to cysteine (31), this
additional cysteine does not increase tissue
GSH levels in mice fed adlibitum.
Analysis ofurine samples collected from
the urinary bladder at necropsy indicated
high concentrations of NAC: 10.5 ± 1.5
mM (range of6-18 mM, n = 7) from mice
that received NAC in their drinkingwater.
Discussion
At present, no effective strategy exists to
promote the rapid clearance of methylmer-
cury from poisoned individuals. A number
ofsulfhydryl-containing complexing agents
have been evaluated extensively and found
to be only marginally effective (7-17). In
contrast, the present study demonstrates
that NAC may be an ideal therapeutic agent
for use in methylmercury poisoning. NAC is
an amino acid derivative that is currently in
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Figure 4. Cumulative (A) urinary and (B) fecal
excretion of 203Hg in mice that received 0.5
pmol/kg body weight of CH3203HgCI. One group of
mice received NAC in the drinking water (10
mg/mI) for the first 48 hr after dosing with
methylmercury, whereas the other group
received N-acetylcysteine (NAC) in the drinking
water from days 2 to 5. Values are means ± stan-
dard errors offive mice in each group.
use in clinical medicine; it is not toxic to
humans, and it is rapidly excreted in urine.
This rapid urinary excretion of NAC most
likely explains its ability to enhance urinary
methylmercury excretion.
Another cysteine derivative, D-penicil-
lamine, was one ofthe earliest agents found
to enhance urinary excretion of methylmer-
cury (7). However, subsequent studies indi-
cated that compounds containing two thiol
groups, such as DMSA and DMPS, are
more effective than D-penicillamine in mobi-
lizing methylmercury from various tissue
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Figure 5. Body burden of methylmercury in female
mice injected intraperitoneally with 25 pmol/kg
body weight of CH3203HgCI. One group of mice
received N-acetylcysteine (NAC) in their drinking
water (10 mg/mI) for the first 48 hr after dosing
with methylmercury, whereas the other group
received NAC in the drinking water from days 2 to
5. Values are means + standard errors of five
mice in each group.
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Figure 6. Body burden of inorganic mercury in
male (M) and female (F) mice injected intraperi-
toneally with 0.5 pmol/kg body weight of203HgC12.
After 48 hr some of the mice received N-acetyl-
cysteine (NAC) in their drinking water (10 mg/mI).
Values are means ± standard errors of four to five
mice in each group.
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compartments and in enhancing its excretion
from the body (8-17). Gabard (11) and
Magos (9) reported that DMSA is effective
in decreasing the body burden and the con-
centration ofmercury in brain, blood, liver,
and kidneys of rats and mice treated with
methylmercury chloride. Aaseth and
Friedheim (13) compared the effects offive
chelating agents in methylmercury-poisoned
mice (DMSA, DMPS, N-acetyl-D,L-penicil-
lamine, mercaptosuccinic acid, and mercap-
tostarch). They also found that DMSA was
superior in accelerating whole-body elimina-
tion and decreasing tissue levels. DMSA
increased the amount ofmercuryexcreted in
urine from 15% ofthe dose in control mice
to 62% in mice that receiveddimercaptosuc-
cinic acid in their food for 8 days (13). In
humans who consumed methylmercury-con-
taminated bread, DMPS was more effective
than D-penicillamine orN-acetyl-D,L-penicil-
lamine in decreasing blood mercury levels
(5). DMPS was also moderately effective at
decreasing blood mercury levels in a case of
acute methylmercury ingestion (17). Because
methylmercury undergoes extensive entero-
hepatic recirculation, a nonabsorbable thiol-
containing resin has also been used success-
filly to bind the mercury excreted into bile
and enhance fecal excretion (5). In humans,
this resin decreased the average elimination
half-time of methylmercury in blood from
65 to 20 days (5). Because of these early
findings with dithiol and polythiol com-
pounds, most subsequent efforts to identify
methylmercury antidotes have focused on
this dass ofchelatingagents.
The present study demonstrates that
NAC may be superior to previously tested
complexing agents. NAC produced a dra-
matic acceleration ofmethylmercury elimi-
nation, with most of the mercury being
excreted in urine. Nearly 90% of the dose
was eliminated in only 2 days when mice
were exposed continuously to NAC in their
drinking water (Fig. 3). This rate of excre-
tion is higher than any previously reported.
Methylmercury excretion was also accelerat-
ed when NAC was given starting at 2 days
after methylmercury exposure, indicating
efficient mobilization from tissue compart-
ments. Of significance, brain levels were
lower in NAC-treated animals, demonstrat-
ing efficient mobilization from the target
organ. However, mobilization from brain
wasslowerthan fromotherorgans (Table 1).
NAC is nontoxic and is currently used
clinically as a mucolytic agent and in the
treatment of acetaminophen overdose
(40,41). It is widely available, relatively
inexpensive, easily administered, and well
tolerated by patients. The clinical pharma-
cology ofNAG is well described (42-45). It
has a volume of distribution of 0.33 l/kg,
indicating distribution mainly to extracellu-
lar water. It is rapidly eliminated in urine,
with approximately one-third excreted in
urine during the first 12 hr after administra-
tion (42). In urine, it is present mostly as
the symmetrical disulfide and as the mixed
disulfide with cysteine, although it is excret-
ed as the free thiol as well (46,47). In
humans the tl/2 for NAC in blood plasma is
approximately 2 hr (42-45). This short half-
life is consistent with the rapid acceleration
ofmethylmercury excretion observed during
NAC administration and with the rapid
deceleration in methylmercury excretion
after NACwithdrawal (Figs. 1, 3, and 5).
In contrast to some dithiol-complexing
agents (18-21), NAC does not alter tissue
distribution ofessential metals (48). Hjortso
et al. (48) measured plasma and urinary con-
centrations oftrace metals (Ga, Mg, Fe, Zn,
and Cu) in healthy human volunteers treated
with NAC for 2 weeks and found no signifi-
cantchange inplasmaconcentration orexcre-
tion of these essential metals. This lack of
effect ofNAC on endogenous divalent metal
ion homeostasis is consistent with its relative-
ly low intrinsic toxicity and indicates that it
may be more selective for monovalent metals
ormetal compoundslikemethylmercury.
It is important to note that oral NAC
was effective in enhancing methylmercury
excretion. Oral administration greatly facili-
tates administration ofthe drug to poisoned
individuals, both in the dinical setting and
in the field. Additional studies are needed to
examine whether NAC might be even more
effective if given intravenously. Additional
studies are also needed to test the efficacy of
NAC after chronic methylmercury exposure
and to determine whether a reduction in tis-
sue levels may be able to reverse methylmer-
cury-induced functional deficits.
In contrast to methylmercury excretion,
clearance of inorganic mercury was not
accelerated by NAC (Fig. 6). Similar find-
ings have been previously reported (22).
The lack of effect on mercuric mercury
excretion is not surprising given the lack of
effect ofNAC on trace divalent metal ion
homeostasis (see above). NAC also has only
relatively small effects on the excretion ofa
variety ofother exogenous metals (25-28).
Thus, NAC might be relatively selective for
methylmercury. Its utility as an antidote
should be examined in the clinical setting.
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Excellence in basic research at the
National Institute of Environmental Health Sciences
NIEHS scientists and grantees perform basic studies of our susceptibility to environment-related disease:
Demonstrating that a carcinogen in cigarette smoke (benzo(a)pyrene) alters part of a gene to cause lung
cancer...showing the effects offetal exposure to PCBs...developing a strain of mouse that lacks functional estrogen
receptors and that helps evaluate how some pesticides and other estrogen-like compounds might affect development
and reproduction...discovering the genes for breast, ovarian, and prostate cancers...finding women' optimal days of
fertility...seeking to reverse the damage from lead exposure...finding alternatives to trad
pinpointing the functions ofspecific genes by eliminating them from specially bred mouse4
using ordinary yeast cells, to isolate and clone genes and other fragments ofgenetic materi
$... tsefurban air on lung function...
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